Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...